TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.

News Market Reaction

-1.95%

1 alert

-1.95% News Effect

On the day this news was published, TCRX declined 1.95%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3^rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T^TM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When is TScan Therapeutics (TCRX) presenting at the H.C. Wainwright Cell Therapy Conference 2025?

TScan Therapeutics will present at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.

How long will TScan Therapeutics' (TCRX) conference webcast be available for replay?

The webcast replay will be available on TScan's website for 90 days following the event.

Where can investors watch TScan Therapeutics' (TCRX) H.C. Wainwright conference presentation?

Investors can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com.

What type of presentation will TScan Therapeutics (TCRX) give at the H.C. Wainwright conference?

TScan Therapeutics will participate in a fireside chat format presentation at the conference.